Cytotoxicity and intracellular fate of PLGA and chitosan‐coated PLGA nanoparticles in Madin–Darby bovine kidney (MDBK) and human colorectal adenocarcinoma (Colo 205) cells

Trif, Mihaela; Florian, Paula; Roșeanu, Anca; Moisei, Magdalena; Crăciunescu, Oana; Astete, Carlos E.; Sabliov, Cristina M.

doi:10.1002/jbm.a.35498

Cited by 37 publications

(23 citation statements)

References 53 publications

(118 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Bone defect reparations have been successfully performed using nanoparticulate systems based on PLGA-coated HAp, providing a rationale for the consideration of PLGA as a coating for organ-targeting delivery systems [10–12]. One of the advantages of mixing PLGA with chitosan within nanoparticulate platforms for controlled delivery of chemotherapeutics in the treatment of cancer is an improved permeation of the cell membrane [22]. The enhanced sialylation of malignant cells [23] benefits the idea of using cationic Ch to target cancer cells and may be the reason behind its occasionally observed anticancer properties [24].…”

Section: Introductionmentioning

confidence: 99%

Selective anticancer activity of hydroxyapatite/chitosan-poly(d,l)-lactide-co-glycolide particles loaded with an androstane-based cancer inhibitor

Ignjatović

Penov-Gaši

et al. 2016

Colloids and Surfaces B: Biointerfaces

View full text Add to dashboard Cite

In an earlier study we demonstrated that hydroxyapatite nanoparticles coated with chitosan-poly(D,L)-lactide-co-glycolide (HAp/Ch-PLGA) target lungs following their intravenous injection into mice. In this study we utilize an emulsification process and freeze drying to load the composite HAp/Ch-PLGA particles with 17β-hydroxy-17α-picolyl-androst-5-en-3β-yl-acetate (A), a chemotherapeutic derivative of androstane and a novel compound with a selective anticancer activity against lung cancer cells. 1H NMR and 13C NMR techniques confirmed the intact structure of the derivative A following its entrapment within HAp/Ch-PLGA particles. The thermogravimetric and differential thermal analyses coupled with mass spectrometry were used to assess the thermal degradation products and properties of A-loaded HAp/Ch-PLGA. The loading efficiency, as indicated by the comparison of enthalpies of phase transitions in pure A and A-loaded HAp/Ch-PLGA, equaled 7.47 wt.%. The release of A from HAp/Ch-PLGA was sustained, neither exhibiting a burst release nor plateauing after three weeks. Atomic force microscopy and particle size distribution analyses were used to confirm that the particles were spherical with a uniform size distribution of d50 = 168 nm. In vitro cytotoxicity testing of A-loaded HAp/Ch-PLGA using MTT and trypan blue dye exclusion assays demonstrated that the particles were cytotoxic to the A549 human lung carcinoma cell line (46±2%), while simultaneously preserving high viability (83±3%) of regular MRC5 human lung fibroblasts and causing no harm to primary mouse lung fibroblasts. In conclusion, composite A-loaded HAp/Ch-PLGA particles could be seen as promising drug delivery platforms for selective cancer therapies, targeting malignant cells for destruction, while having a significantly lesser cytotoxic effect on the healthy cells.

show abstract

Section: Introductionmentioning

confidence: 99%

Selective anticancer activity of hydroxyapatite/chitosan-poly(d,l)-lactide-co-glycolide particles loaded with an androstane-based cancer inhibitor

Ignjatović

Penov-Gaši

et al. 2016

Colloids and Surfaces B: Biointerfaces

View full text Add to dashboard Cite

show abstract

“…In a study, researchers assessed cellular uptake and trafficking of PLGA NPs and chitosan (Chi)-covered PLGA NPs in human colorectal adenocarcinoma cells (COLO-205). 52 Neither Chi-PLGA nor PLGA NPs were toxic to the assessed cells at concentrations of up to 2,500 μg/mL. This study offered novel insights into the interaction of NPs with target cells, sustaining the use of NPs as new drug-delivery systems in cancer therapy.…”

Section: Applications Of Plga Nanoparticles/nanocellsmentioning

confidence: 82%

“…This study offered novel insights into the interaction of NPs with target cells, sustaining the use of NPs as new drug-delivery systems in cancer therapy. 52 In another study, Tang In a study, researchers proposed the use of PLGA-based polymeric oil-core nanocapsules (NCs) for curcumin loading and delivery to CRC in mice after systemic injection. 54 Their findings specify that castor oil-core PLGA-based NCs provide elevated drug-loading efficiency and that the curcuminloaded NCs are more effective against CT26 cells than the free drug and apply therapeutic activity in vitro, leading to apoptosis and blockade of the cell cycle.…”

Section: Applications Of Plga Nanoparticles/nanocellsmentioning

confidence: 99%

Recent insights into nanotechnology development for detection and treatment of colorectal cancer

Viswanath¹,

Kim²,

Lee³

2016

IJN

View full text Add to dashboard Cite

The global incidence of colorectal cancer (CRC) is 1.3 million cases. It is the third most frequent cancer in males and females. Most CRCs are adenocarcinomas and often begin as a polyp on the inner wall of the rectum or colon. Some of these polyps become malignant, eventually. Detecting and removing these polyps in time can prevent CRC. Therefore, early diagnosis of CRC is advantageous for preventive and instant action interventions to decrease the mortality rates. Nanotechnology has been enhancing different methods for the detection and treatment of CRCs, and the research has provided hope within the scientific community for the development of new therapeutic strategies. This review presents the recent development of nanotechnology for the detection and treatment of CRC.

show abstract

“…Similar results were also reported previously, i.e., that pristine PLGA NPs below 1,000 g/mL were not toxic to cells of four different lines after 24 h of incubation, indicating PLGA to be a biocompatible and biodegradable polymer with low cytotoxicity. 22 All subsequent in vitro tests therefore used NPs at a clearly non-cytotoxic concentration of 50 g/mL.…”

Section: Resultsmentioning

confidence: 99%

In vitro evaluation of lysyl oxidase antibody conjugated nanoparticles

Kim

Park

et al. 2016

Macromol. Res.

View full text Add to dashboard Cite

In this study, we prepared poly(lactic-co-glycolic acid) (PLGA) nanoparticles (NPs) conjugated to lysyl oxidase-inhibiting antibodies (LOX ab ) as an anticancer therapy in order to efficiently inhibit the growth of mammary cancer cells. Scanning electron microscopy and dynamic light scattering analysis showed that the antibody-conjugated NPs tested were stable and round, with a mean diameter of 165 nm and surface charge of -15 mV, compared with values of 143 nm and -17 mV for pristine NPs. The pristine NPs at concentrations less than 1,000 ug/ml showed low cytotoxicity and were effectively internalized into cancer cells. Our in vitro studies showed that the LOX ab conjugated NPs were two to three times more suppressive of lung, colorectal and breast cancer cells than was the soluble antibody at the same dose. Taken together, our results suggest that NPs conjugated to LOX ab constitute a promising nano-therapeutic candidate for inhibiting the growth of mammary cancer cells.

show abstract

Cytotoxicity and intracellular fate of PLGA and chitosan‐coated PLGA nanoparticles in Madin–Darby bovine kidney (MDBK) and human colorectal adenocarcinoma (Colo 205) cells

Cited by 37 publications

References 53 publications

Selective anticancer activity of hydroxyapatite/chitosan-poly(d,l)-lactide-co-glycolide particles loaded with an androstane-based cancer inhibitor

Selective anticancer activity of hydroxyapatite/chitosan-poly(d,l)-lactide-co-glycolide particles loaded with an androstane-based cancer inhibitor

Recent insights into nanotechnology development for detection and treatment of colorectal cancer

In vitro evaluation of lysyl oxidase antibody conjugated nanoparticles

Contact Info

Product

Resources

About